Print

96-I-0050

Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) March 16, 1996
APL 400-003 GENEVAX-HIV env,rev
APL 400-003 GENEVAX-HIV DNA
USA 41
NCT00001538
http://clinicaltrials.gov/ct2/show/NCT00001538